Skip to main content

EDITORIAL article

Front. Genet., 10 May 2024
Sec. Neurogenomics
This article is part of the Research Topic Multifaceted Genes in Amyotrophic Lateral Sclerosis-Frontotemporal Dementia Volume II View all 5 articles

Editorial: Multifaceted genes in amyotrophic lateral sclerosis-frontotemporal dementia volume II

  • 1Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, Arcavacata di Rende, Italy
  • 2Icahn School of Medicine at Mount Sinai, New York, NY, United States
  • 3University College London, London, England, United Kingdom

Building on the first Volume of Multifaceted Genes in Amyotrophic Lateral Sclerosis-Frontotemporal Dementia, this new Research Topic includes papers focusing on the most common genetic cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) in European ancestry populations, the C9orf72 hexanucleotide repeat expansion mutation. Broce et al. explored the neuroanatomical basis of shared genetic risk in the ALS-FTD spectrum by identifying genes exhibiting regional co-expression patterns similar to C9orf72. Aiming to elucidate why certain brain regions are susceptible to neurodegeneration in C9orf72-linked ALS-FTD, the authors uncovered a C9orf72-associated gene network that also tracked cortical thickness in C9orf72 repeat expansion carriers. Finally, they showed that this network was enriched in brain cell populations and regions known to be selectively vulnerable in ALS-FTD, and investigated the molecular pathways involved.

Another interesting aspect concerns C9orf72 intermediate-length repeat alleles in ALS-FTD. Their precise role remains unknown, but these alleles are much more frequent than the repeat expansion. Therefore, if they pose a disease risk, a significant proportion of ALS patients could benefit from treatments in development that target the C9orf72 repeat expansion. In the Finnish population, Kaivola et al. identified a haplotype containing a subset of intermediate-length alleles that increases the risk of ALS. The authors also showed in the FinnGen biobank cohort that this haplotype reduces survival after the age of 80, which may have implications for neurodegenerative diseases other than ALS-FTD.

This Research Topic also focuses on other genetic loci contributing to the disorders. In particular, the study by Miura et al. reports a sporadic case of ALS-FTD carrying a p. Arg89Trp missense variant in the VCP gene. VCP genetic variants predicted to alter this amino acid residue have previously been found in patients diagnosed with FTD-distal myopathy and with ALS, further demonstrating that this gene can cause phenotypic pleiotropy. This underscores the importance of studying VCP genetic variants in patients with ALS and FTD, even in those without a family history of these diseases.

In addition, Brusati et al. highlighted the contribution of microRNA (miRNA) genetic variation to ALS. In this study, the authors developed a workflow to detect miRNA rare variants in ALS whole genome sequencing data and predict their biological effects on miRNA folding, maturation, and target gene recognition. This approach suggests that ALS-carriedmiRNA rare variantsimpact nervous system development, although these preliminary findings await confirmation and functional validation.

The four articles in this Research Topic expand our understanding of the genetic architecture and genotype-phenotype relationships of ALS-FTD. These findings help move the field forward as we progress toward precision medicine approaches to combat these devastating diseases.

Author contributions

FC: Writing–original draft, Writing–review and editing. AR: Writing–review and editing. HH: Writing–review and editing.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: C9ORF72 ALS/FTD, FTD (frontotemporal dementia), ALS (amyotrophic lateral sclerosis), miRNA, microRNA, missence variant

Citation: Conforti FL, Renton AE and Houlden H (2024) Editorial: Multifaceted genes in amyotrophic lateral sclerosis-frontotemporal dementia volume II. Front. Genet. 15:1420029. doi: 10.3389/fgene.2024.1420029

Received: 19 April 2024; Accepted: 26 April 2024;
Published: 10 May 2024.

Edited and reviewed by:

Sarah H. Elsea, Baylor College of Medicine, United States

Copyright © 2024 Conforti, Renton and Houlden. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Francesca Luisa Conforti, francescaluisa.conforti@unical.it; Alan Edward Renton, alan.renton@mssm.edu; Henry Houlden, h.houlden@ucl.ac.uk

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.